Hypothesis

The superior senolytic activity of quercetin phytosome stems not from higher peak concentration but from its extended plasma exposure (greater AUC and later Tmax), which maintains sufficient quercetin levels to continuously inhibit NF‑κB‑driven SASP and sustain Nrf2‑mediated antioxidant responses, ultimately leading to deeper clearance of p16^INK4a^‑positive cells than achievable with standard aglycone or isoquercetin.

Mechanistic Rationale

1. Kinetic advantage of phytosome – LipoMicel formulation yields ~7‑fold higher AUC (543 ng·h/mL) versus aglycone (77 ng·h/mL) and a later Tmax (~6 h vs 3 h) [2]. This creates a prolonged window where plasma quercetin exceeds the putative senolytic threshold (estimated ~20 µM from in‑vitro SA‑β‑gal reduction) [4].
2. Sustained NF‑κB suppression – Quercetin blocks IκB kinase activity; continuous exposure prevents the rebound NF‑κB activation that fuels SASP autocrine loops, thereby lowering IL‑6, IL‑8 and MCP‑1 levels over time. The phytosome’s tail‑end concentration keeps this inhibition active longer than the brief spike from aglycone.
3. Nrf2 prolonging effect – Quercetin modifies Keap1 cysteines, stabilizing Nrf2 and driving HO‑1, NQO1 expression. A longer exposure cumulatively boosts cellular redox capacity, reducing ROS‑induced senescence reinforcement and sensitizing cells to apoptotic clearance.
4. NAD+‑SIRT1 axis – Quercetin inhibits CD38, preserving NAD+. Sustained NAD+ elevation supports SIRT1 deacetylation of p53 and FOXO, promoting senescent cell apoptosis. The phytosome’s extended AUC maintains NAD+ levels above the critical threshold for SIRT1 activity longer than aglycone’s rapid decline.
5. Isoquercetin limitation – Although isoquercetin converts to quercetin, its rapid glucuronidation yields minimal parent exposure and a sharp, short‑lived quercetin pulse [3]. This fails to maintain the inhibitory concentration needed for prolonged NF‑κB/Nrf2 modulation, explaining its lack of apparent senolytic benefit despite comparable total quercetin AUC in rats.

Testable Prediction

In a randomized, crossover trial with older adults (n = 30), participants will receive single oral doses of (a) quercetin phytosome 500 mg, (b) quercetin aglycone 500 mg, and (c) isoquercetin 500 mg, separated by ≥2‑week washouts. Plasma quercetin PK (Cmax, AUC₀‑₂₄, Tmax) will be measured. Twenty‑four hours post‑dose, peripheral blood mononuclear cells will be assayed for p16^INK4a^ mRNA, SIRT1 activity, NAD+ levels, and SASP cytokines (IL‑6, IL‑8). Skin punch biopsies will be stained for SA‑β‑gal. We hypothesize that phytosome will show a statistically significant inverse correlation between AUC₀‑₂₄ and p16^INK4a^ expression (r < ‑0.5, p < 0.01), while aglycone and isoquercetin will exhibit weaker or non‑significant relationships. A mediating analysis will test whether sustained Nrf2 nuclear occupancy (measured via flow cytometry) accounts for >40 % of the AUC‑senolysis link.

Falsifiability

If phytosome’s AUC does not predict greater p16^INK4a^ reduction or SASP suppression compared to aglycone/isoquercetin after controlling for Cmax, or if isoquercetin shows equivalent senolytic outcomes despite its rapid glucuronidation, the hypothesis would be refuted. Similarly, failure to observe prolonged Nrf2 activation or NAD+ elevation matching the phytosome’s PK profile would invalidate the proposed mechanistic chain.